SCHEMBL134146

SCHEMBL134146

COc1cc(/C=C/c2nc3ccccc3c(=O)o2)ccc1O

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.67
▸ RAB9A P51151 4/20 0.67
▸ ELANE P08246 1/20 0.61
▸ MEN1 O00255 9/20 0.59
▸ KMT2A Q03164 9/20 0.59
▸ GAA P10253 1/20 0.59
▸ MAPT P10636 3/20 0.56
▸ GLA P06280 1/20 0.56
▸ PKM P14618 1/20 0.56
▸ MCL1 Q07820 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ HSP90AA1 P07900 1/20 0.55
▸ HPGD P15428 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ APP P05067 1/20 0.52
▸ ATM Q13315 1/20 0.52
▸ XBP1 P17861 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1589854 0.90 NPC1 (0.72) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL1589852 0.90 NPC1 (0.72) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL12723717 0.88 NPC1 (0.70) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL19695932 0.86 ELANE (0.57) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL1589946 0.86 NPC1 (0.71) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL1590366 0.86 NPC1 (0.71) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL1589944 0.86 NPC1 (0.71) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL1590369 0.86 NPC1 (0.71) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL13556324 0.85 ELANE (0.65) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL19695931 0.84 APP (0.49) NPC1RAB9AMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9839640-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation OCCURX PTY LTD (AU) 2017-12-12 — — US disclosed
US-9062076-B2 Fused ring analogues of anti-fibrotic agents FIBROTECH THERAPEUTICS PTY LTD (AU) 2015-06-23 — — US disclosed
US-8420850-B2 Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers Iberhospitex, S.A (ES) 2013-04-16 — — US disclosed
US-8420850-B2 Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers Iberhospitex, S.A (ES) 2013-04-16 — — US disclosed
US-20120270863-A1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS FIBROTECH THERAPEUTICS PTY LTD (AU) 2012-10-25 — — US disclosed
US-20120059117-A1 COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS IBERHOSPITEX, S.A. 2012-03-08 — — US disclosed
US-20120059117-A1 COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS IBERHOSPITEX, S.A. 2012-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270863-A1 FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS MMP1, FIBP, COL2A1 NPC1 1936/4885RAB9A 2239/4885ELANE 35/4885
US-20120059117-A1 COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS PUF60, UMPS, UGP2 NPC1 4694/4885RAB9A 4356/4885ELANE 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback